SCHEMBL10083508

SCHEMBL10083508

CCc1cccc(NC(=O)C(C)C)n1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.51
CHRNB4 P30926 2/20 0.51
CHRNA3 P32297 2/20 0.51
CHRNA4 P43681 2/20 0.51
XIAP P98170 1/20 0.49
BIRC2 Q13490 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
SYK P43405 1/20 0.45
ADORA1 P30542 2/20 0.44
ADORA3 P0DMS8 1/20 0.44
ADORA2A P29274 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
FAAH O00519 1/20 0.43
NR3C2 P08235 1/20 0.42
ATR Q13535 1/20 0.41
RAB9A P51151 1/20 0.41
MAPK8 P45983 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23619520 0.87 XIAP (0.49) CHRNB2CHRNB4CHRNA3CHRNA4XIAP
SCHEMBL3111821 0.83 CHRNB2 (0.56) CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2
SCHEMBL20557489 0.81 SMN1; SMN2 (0.53) XIAPBIRC2SMN1; SMN2ADORA1ADORA3
SCHEMBL7895323 0.81 MAPK8 (0.59) CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2
SCHEMBL10082887 0.81 SMN1; SMN2 (0.77) CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2
SCHEMBL5032590 0.80 NR3C2 (0.57) CHRNB2CHRNB4CHRNA3CHRNA4XIAP
SCHEMBL6361201 0.80 CHRNB2 (0.53) CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2
SCHEMBL24598576 0.78 RAB9A (0.68) XIAPBIRC2SMN1; SMN2FAAHRAB9A
SCHEMBL91504 0.77 CHRNB2 (0.54) CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2
SCHEMBL4171284 0.77 CHRNB2 (0.51) CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207267-A1 (R)-Glutarimide CRBN Ligands and Methods of Use BEIGENE SWITZERLAND GMBH (CH) 2024-06-27 US disclosed
US-20240207267-A1 (R)-Glutarimide CRBN Ligands and Methods of Use BEIGENE SWITZERLAND GMBH (CH) 2024-06-27 US disclosed
US-8119646-B2 Fungicide hydroximoyl-tetrazole derivatives BAYER CROPSCIENCE AG (DE) 2012-02-21 US disclosed
US-20090258875-A1 Fungicide Hydroximoyl-Tetrazole Derivatives BAYER CROPSCIENCE AG (DE) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207267-A1 (R)-Glutarimide CRBN Ligands and Methods of Use CRBN, CDR2, CRKL CHRNB2 456/4885CHRNB4 721/4885CHRNA3 1137/4885
US-20090258875-A1 Fungicide Hydroximoyl-Tetrazole Derivatives HAAO, CYP51A1, CYP8B1 CHRNB2 4648/4885CHRNB4 4707/4885CHRNA3 4123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.